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Abstract: Usnic acid (UA) is a secondary metabolite of lichens that exhibits a wide range of biological
activities. Previously, we found that UA derivatives are effective inhibitors of tyrosyl-DNA phos-
phodiesterase 1 (TDP1). It can remove covalent complex DNA-topoisomerase 1 (TOP1) stabilized
by the TOP1 inhibitor topotecan, neutralizing the effect of the drugs. TDP1 removes damage at the
3′ end of DNA caused by other anticancer agents. Thus, TDP1 is a promising therapeutic target for
the development of drug combinations with topotecan, as well as other drugs for cancer treatment.
Ten new UA enamino derivatives with variation in the terpene fragment and substituent of the UA
backbone were synthesized and tested as TDP1 inhibitors. Four compounds, 11a-d, had IC50 values
in the 0.23–0.40 µM range. Molecular modelling showed that 11a-d, with relatively short aliphatic
chains, fit to the important binding domains. The intrinsic cytotoxicity of 11a-d was tested on two
human cell lines. The compounds had low cytotoxicity with CC50 ≥ 60 µM for both cell lines. 11a
and 11c had high inhibition efficacy and low cytotoxicity, and they enhanced topotecan’s cytotoxicity
in cancerous HeLa cells but reduced it in the non-cancerous HEK293A cells. This “protective” effect
from topotecan on non-cancerous cells requires further investigation.
Keywords: usnic acid; tyrosyl-DNA phosphodiesterase 1; TDP1 inhibitor; inhibiting activity; terpene;
topotecan; synergy
1. Introduction
Usnic acid (UA, 1, Figure 1) is a specific lichen metabolite. This bioactive substance
is produced in large quantities by the lichen mycobiont, accounting for up to 8% of the
dry weight of thalli. UA has antioxidant, antiviral, antibiotic, analgesic, antituberculo-
sis, insecticidal, and anticancer activities [1,2], but with hepatotoxicity in high doses [3].
The main method of obtaining UA is the extraction from various genera of lichens such as
Cladonia (Cladoniaceae), Usnea (Usneaceae), and others with organic solvents [4]. UA is a
yellow crystalline substance with two enantiomeric forms differing in the orientation of the
angular methyl group. Generally, only one of the enantiomers is isolated from each lichen
species. The (+)-UA enantiomer is prevalent in nature and is commercially available [5].
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Figure 1. Structures of usnic acid (1) and its derivatives (2–5) that inhibit TDP1.
Chemical modification of UA results in highly active derivatives against mycobacte-
ria [6], viruses [7,8], and insects [9]; practically all the derivatives are less generally toxic
than their parent [10,11].
Previously, we found that UA derivatives 2–5 (Figure 1) are effective inhibitors of
tyrosyl-DNA phosphodiesterase 1 (TDP1) [12–15]. TDP1 plays a key role in DNA damage
repair caused by antitumor drugs, such as the camptothecin derivatives [16,17]—topotecan
(Tpc) and irinotecan. These drugs inhibit topoisomerase 1 (TOP1) that regulates the degree
of local DNA torsion. A covalent DNA–TOP1 complex is formed [18], which is stabilized
by the camptothecins, preventing the recovery of the DNA strand. Thus, DNA damage
is preserved in the form of covalent adducts and single-strand breaks, leading to cell
cycle arrest and death [18,19]. TDP1 can remove the DNA–TOP1 complex from the 3′
end, neutralizing the effect of TOP1 inhibitors [20]. Therefore, TDP1 can cause cellular
resistance, and its suppression has the potential to enhance the therapeutic effect of the
camptothecin analogs [21,22] Tpc and irinotecan [23], which are used in a range of tumors
including lung cancer, colon cancer, cervical cancer, and ovarian cancer.
UA derivatives are highly effective TDP1 inhibitors (Figure 1) at low micromolar
and nanomolar concentrations. We chemically modified UA to improve TDP1 inhibition
and reduce general cytotoxicity [12,13,15,24]. Previously, we showed synergistic effects
of UA derivatives with camptothecin or Tpc in vitro (compounds 3–5, Figure 1) [12–15]
and in vivo with Tpc (compounds 4 and 5b, Figure 1) [12,25]. The hydrazinothiazole UA
derivative with para-bromophenyl as the Ar ring (4 in Figure 1) enhanced the antitumor and
antimetastatic effect of Tpc in the mice Lewis lung carcinoma model [12]. Moreover, Tpc and
4 had an antitumor effect on Krebs 2 ascites tumors in mice separately; their combination
considerably increased the antitumor potential [26]. Another UA derivative, an enamine
with 3,5-di-tert-butyl-4-hydroxyphenyl substituent (5b, Figure 1), demonstrated a strong
antimetastatic activity, under various administration schedules, by intravenous injection in
mice with Lewis lung carcinoma [25]. Thus, UA-based TDP1 inhibitors can be considered
promising for the development of combined antitumor therapy.
Monoterpenoids are often used as starting molecules for the synthesis of new effective
agents for the treatment of a wide range of diseases [27]; their use in drug design frequently
reduces the toxicity of the resulting molecules. Various monoterpenoid-based TDP1 in-
hibitors (compounds 6–8, Figure 2) are effective at submicromolar concentrations [28–30].
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Figure 2. Structures of TDP1 inhibitors with monoterpenoid moieties.
Previously, our team synthesized UA derivatives containing terpene fragments on
ring A of the benzofuran backbone, hydrazinothiazole 9, and aurone 10 (Figure 3) [31,32].
It was shown that substitution of UA with terpenes led to an increase in inhibitory activity
(compound 9) and to a decrease in the intrinsic cytotoxicity (compound 9 and 10) compared
to their aromatic (heteroaromatic) counterparts 2 and 4 (Figure 1).
Figure 3. Structures of usnic acid and monoterpenoid conjugates that inhibit TDP1.
UA enamine derivatives 5 are also effective [15]—they differ from the already men-
tioned aurones 2 and hydrazinothiazoles 4 by modification of the dibenzofuran backbone
on the C ring. The IC50 values for these compounds ranged from 0.2 to 2 µM, and their
distinctive feature is up to 12-fold sensitization of the MCF-7 (breast cancer) cells to Tpc [15].
The aim of this work was to synthesize enamino derivatives of UA with terpene frag-
ments with variation both in the structure of the terpene fragment (linear, monocyclic,
bicyclic) and to the location on the UA scaffold (directly or via a linker) and gauge their
TDP1 inhibiting potential. Furthermore, cytotoxicity and sensitizing effects of cancer cell
lines with Tpc were studied.
2. Materials and Methods
2.1. General Information
The analytical and spectral studies were conducted in the Chemical Service Center for
the collective use of Siberian Branch of Russian Academy of Sciences.
The 1H and 13C NMR spectra in CDCl3 were recorded on a Bruker AVANCE III
400 spectrometer (Bruker Corporation, Germany; 400.13 and 100.61 MHz, respectively).
The residual signals of the solvent were used as references (δH 7.24 and δC 76.9, respectively,
for CDCl3). The mass spectra (70 eV) were recorded on a DFS Thermo Scientific high-
resolution mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). = Macherey-Nagel
silica gel (63–200 µ) was used for the column chromatography. Thin-layer chromatography was
performed on TLC Silica gel 60 plates (UV-254, Merck, Darmstadt, Germany).
All chemicals were used as described unless otherwise noted. Reagent-grade solvents
were redistilled prior to use. Synthetic starting materials, reagents, and solvents were
purchased from Sigma-Aldrich (St. Louis, MO, USA), Acros Organics (Geel, Belgium),
and AlfaAesar (Heysham, UK). (R)-(+)-Usnic acid 1 (αD +478 (c 0.1, CHCl3)) was iso-
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lated from a mixture of lichen genus Usnea by the Salakhutdinov et al. procedure [33].
Compound 12 was synthesized according to the literature [34]. Terpenoid amines were
synthesized according to Suslov et al. [35].
The atom numbers in the compound are provided for the assignment of signals in the
NMR spectra and are different from the numeration in the nomenclature name.
2.2. Chemistry
2.2.1. General Procedure for the Synthesis of Enamine Compounds 11a–e
Usnic acid 1 (1 mmol), terpene amine (1.2 mmol), and NEt3 (0.2 mmol) were added to
a dry flask. The mixture was dissolved in 10 mL of ethyl alcohol (95%) and boiled. After
2 h, the mixture was cooled, and aqueous hydrochloric acid was added to the mixture.
The precipitate was filtered off, washed with water, and then air dried. The resulting solid
was purified by chromatography over silica gel with CH2Cl2 to obtain desired products
11a–e (Figure 4).
(2R,4E)-10-Acetyl-4-(1-{[(3S)-3,7-dimethyloct-6-en-1-yl]amino}ethylidene)-11,13-dihydroxy-2,12-
dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(13),6,9,11-tetraene-3,5-dione 11a: Yellow amorphous
powder with a 75% yield. NMR 1H: see Table 1. NMR 13C: see Table 2. HRMS: m/z 481.2457
[M]+ (calcd. for (C28H35O6N)+: 481.2459).
Table 1. NMR 1H spectra of 11a–e.
№ a b c d e
Structure
H-16 3.45, m 4.0, m 3.44, m 3.95, m 3.94, m
H-17 1.15–1.52, m 5.28, m 2.18–2.38, m — —
H-18 1.73, m — — 5.47, ss 5.67, ss
H-19 1.15–1.52, m 2.08, s 5.44, s 2.30, m 1.94–2.20, m
H-20 1.99, m 2.09, s 2.18–2.38, m 2.44, m 1.94–2.20, m
H-21 5.06, m 5.05, m 2.18–2.38, m — 1.50, m and 1.86,m
H-22 — — — 2.0, m 1.94–2.20, m
H-23 1.59, s 1.58, s 2.0, m 1.2 d (8.9) and 2.1,m —
H-24 0.94, d (6.25) 1.65, s 1.1, d (8.6) and2.1, m 0.84, s 4.7, d (13.5)
H-25 1.68, s 1.77, s 0.78, s 1.29, s 1.71, s
H-26 — — 1.25, s — —
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Figure 4. Structures of compounds 11a–e with atom numeration.
Table 2. NMR 13C spectra of 11a–e.
№ a b c d e
Structure
C-16 42.00 41.8 45.2 48.4 49.5
C-17 36.6 117.0 35.7 120.2 148.9
C-18 31.9 142.15 120.4 141.5 125.0
C-19 35.8 39.2 143.0 31.4 30.2
C-20 25.2 26.0 31.2 40.5 40.5
C-21 123.9 123.2 40.5 38.1 26.9
C-22 131.7 132.0 38.0 44.0 27.0
C-23 17.6 25.6 42.0 31.9 131.1
C-24 25.6 16.5 32.0 18.8 108.9
C-25 18.2 17.6 18.4 25.9 18.1
C-26 — — 26.1 — —
(2R,4E)-10-Acetyl-4-(1-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]amino}ethylidene)-11,13-dihydroxy-
2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(13),6,9,11-tetraene-3,5-dione 11b: Yellow amor-
phous powder with a 68% yield. NMR 1H: see Table 1. NMR 13C: see Table 2. HRMS: m/z
479.2295 [M]+ (calcd. for (C28H33O6N)+: 479.2302).
(2R,4E)-10-Acetyl-4-[1-({2-[(1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl]ethyl}amino)
ethylidene]-11,13-dihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(13),6,9,11-tetraene-3,5-
dione 11c: Yellow amorphous powder with a 92% yield. NMR 1H: see Table 1. NMR 13C:
see Table 2. HRMS: m/z 491.2307 [M]+ (calcd. for (C29H33O6N)+: 491.2302).
(2R,4E)-10-Acetyl-4-[1-({[(1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl]methyl}amino)
ethylidene]-11,13-dihydroxy-2,12-dimethyl-8-oxatricyclo[7.4.0.02,7]trideca-1(13),6,9,11-tetraene-3,5-
dione 11d: Yellow amorphous powder with a 66% yield. NMR 1H: see Table 1. NMR 13C:
see Table 2. HRMS: m/z 477.2146 [M]+ (calcd. for (C28H31O6N)+: 477.2144).
(2R,4E)-10-Acetyl-11,13-dihydroxy-2,12-dimethyl-4-[1-({[(4S)-4-(prop-1-en-2-yl)cyclohex-1-en-1-
yl]methyl}amino)ethylidene]-8-oxatricyclo[7.4.0.02,7]trideca-1(13),6,9,11-tetraene-3,5-dione 11e:
Yellow amorphous powder with a 33% yield. NMR 1H: see Table 1. NMR 13C: see Table 2.
HRMS: m/z 477.2146 [M]+ (calcd. for (C24H18O8N432S2)+: 477.2151).
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2.2.2. NMR Spectra of Compounds 11a–e
NMR 1H (CDCl3, δ): 1.7 (3H, s, H-15), 2.1 (3H, s, H-10), 2.6 (3H, s, H-12), 2.6 (3H, s,
H-14), 5.8 (1H, s, H-4), 12.0 (1H, s, OH-9), 13.3 (2H, s and ss, OH-7 and NH). NMR 13C
(CDCl3, δ): 7.4 (C-10), 20.9 (C-12), 31.1 (C-15), 31.2 (C-12), 56.6 (C-9b), 101.2 (C-9a), 102.1
(C-6), 102.4 (C-4), 105.0 (C-8), 107.8 (C-2), 155.8 (C-7), 158.2 (C-9), 163.3 (C-5a), 173.8 (C-11),
174.5 (C-4a), 189.4 (C-3), 198.0 (C-1), 200.6 (C-11).
2.2.3. General Procedure for the Synthesis of Enamine Compounds 13a–e
Usnic acid enamine 12 (1 mmol), terpene amine (1.3 mmol), 1-(3-dimethylaminopropyl)-
3-ethylcarbodiimide hydrochloride (EDC) (1.45 mmol), and 4-dimethylaminopyridine
(0.05 mmol) were dissolved in CH2Cl2 (10 mL) under argon. The mixture was stirred at
0 ◦C for 2 h. After that, mixture was stirred overnight at room temperature. The resulting
mixture was washed with dilute HCl (0.1 M), aqueous NaHCO3 (0.1 M) and then brine.
The combined organic extracts were dried over anhydrous Na2SO4, and the solvent was
removed under reduced pressure. The resulting mixture was purified by chromatography
over silica gel with CH2Cl2 to obtain desired products 13a–e (Figure 5).
(3R)-3,7-Dimethyloct-6-en-1-yl 4-({1-[(2R,4E)-10-acetyl-11,13-dihydroxy-2,12-dimethyl-3,5-dioxo-
8-oxatricyclo[7.4.0.02,7]trideca-1(13),6,9,11-tetraen-4-ylidene]ethyl}amino)butanoate 13a: Yellow
amorphous solid with a 53% yield. NMR 1H: see Table 3. NMR 13C: see Table 4. HRMS:
m/z 567.2824 [M]+ (calcd. for (C32H41O8N)+: 567.2827).
Table 3. NMR 1H spectra of 13a-e.
№ a b c d e
Structure
H-16 4.10, m 4.61, m 4.01, m 4.45, m 4.45, m
H-17 1.15−1.52, m 5.31, m 2.10−2.30, m — —
H-18 1.68, m — — 5.55, m 5.73, s
H-19 1.15−1.52, m 2.09, s 5.27, s 2.25, m 1.86−2.17, m
H-20 1.95, m 2.09, s 2.10−2.30, m 2.38, m 1.86−2.17, m
H-21 5.06, m 5.06, m 2.40, m — 1.44, m and 1.80, m
H-22 — — — 2.0, m 1.86−2.17, m
H-23 1.57, s 1.57, s 2.0, m 1.1 d (8.9)and2.1, m —
H-24 0.96, d (6.5) 1.65, s 1.1, d (8.6)and2.1, m 0.78, s 4.68, m
H-25 1.65, s 1.68, s 0.78, s 1.28, s 1.69, s
H-26 — 1.23, s — —
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Figure 5. Structures of compounds 13a-e with atom numeration.
Table 4. NMR 13C spectra of 13a–e.
№ a b c d e
Structure
C-16 63.3 61.7 63.0 67.3 68.65
C-17 36.8 117.7 35.7 121.8 149.1
C-18 31.7 142.7 118.8 142.5 126.1
C-19 35.2 39.4 143.7 31.1 30.2
C-20 25.2 26.1 31.2 42.9 40.5
C-21 124.3 123.5 40.5 37.9 26.2
C-22 131.3 132.8 37.8 43.4 27.0
C-23 17.5 25.6 45.4 31.8 132.1
C-24 25.6 16.4 32.0 18.5 108.9
C-25 18.1 17.6 18.2 25.9 18.0
C-26 — — 26.1 — —
(2E)-3,7-Dimethylocta-2,6-dien-1-yl 4-({1-[(2R,4E)-10-acetyl-11,13-dihydroxy-2,12-dimethyl-3,5-
dioxo-8-oxatricyclo[7.4.0.02,7]trideca-1(13),6,9,11-tetraen-4-ylidene]ethyl}amino)butanoate 13b:
Yellow amorphous solid with a 45% yield. NMR 1H: see Table 3. NMR 13C: see Table 4.
HRMS: m/z 565.2667 [M]+ (calcd. for (C32H39O8N)+: 565.2670).
2-[(1R,5S)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-yl]ethyl 4-({1-[(2R,4E)-10-acetyl-11,13-dihydroxy-
2,12-dimethyl-3,5-dioxo-8-oxatricyclo[7.4.0.02,7]trideca-1(13),6,9,11-tetraen-4-ylidene]ethyl}amino)
butanoate 13c: Yellow amorphous solid with a 69% yield. NMR 1H: see Table 3. NMR 13C:
see Table 4. HRMS: m/z 577.2668 [M]+ (calcd. for (C33H39O8N)+: 577.2670).
[(1R,5S)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-yl]methyl 4-({1-[(2R,4E)-10-acetyl-11,13-dihydroxy-
2,12-dimethyl-3,5-dioxo-8-oxatricyclo[7.4.0.02,7]trideca-1(13),6,9,11-tetraen-4-ylidene]ethyl}
amino)butanoate 13d: Yellow amorphous solid with a 53% yield. NMR 1H: see Table 3.
NMR 13C: see Table 4. HRMS: m/z 563.517 [M]+ (calcd. for (C32H37O8N)+: 563.2514).
[(4S)-4-(Prop-1-en-2-yl)cyclohex-1-en-1-yl]methyl 4-({1-[(2R,4E)-10-acetyl-11,13-dihydroxy-2,12-
dimethyl-3,5-dioxo-8-oxatricyclo[7.4.0.02,7]trideca-1(13),6,9,11-tetraen-4-ylidene]ethyl}amino)
butanoate 13e: Yellow amorphous powder with a 68% yield. NMR 1H: see Table 3. NMR
13C: see Table 4. HRMS: m/z 563.2508 [M]+ (calcd. for (C32H39O8N)+: 563.2514).
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2.2.4. NMR Spectra of Compounds 13a–e
NMR 1H (CDCl3, δ): 1.7 (3H, s, H-15), 2.1 (3H, s, H-10), 2.1 (2H, p, J = 6.9 Hz), 2.6
(3H, s, H-12), 2.6 (3H, s, H-14), 2.45 (2H, t, J = 6.9 Hz), 3.52 (2H, m, H-16), 5.8 (1H, s, H-4),
12.0 (1H, s, OH-9), 13.3 (2H, s and ss, OH-7 and NH). NMR 13C (CDCl3, δ): 7.4 (C-10), 20.9
(C-12), 24.2 (C-17), 30.8 (C-18), 31.1 (C-15), 31.2 (C-12), 42.9 (C-16), 56.6 (C-9b), 101.2 (C-9a),
102.1 (C-6), 102.4 (C-4), 105.0 (C-8), 107.8 (C-2), 155.8 (C-7), 158.2 (C-9), 163.3 (C-5a), 172.1
(C-19), 173.8 (C-11), 174.5 (C-4a), 189.4 (C-3), 198.0 (C-1), 200.6 (C-11).
2.3. Biology
2.3.1. Real-Time Detection of TDP1 Activity
The oligonucleotide biosensor 5′-FAM-AAC GTC AGG GTC TTC C- BHQ1-3′ was
used for TDP1 enzyme activity real-time fluorescence detection [36], that is, a 16-mer
single-stranded oligonucleotide with a 5′-fluorophore (FAM), and a 3′-quencher (BHQ1).
Recombinant protein TDP1 was expressed in E. coli (pET 16B) plasmid containing TDP1
cDNA, kindly provided by Dr. K.W. Caldecott (University of Sussex, United Kingdom) and
isolated as described [37]. The final volume of 200 µL of reaction mixture contained TDP1
reaction buffer (50 mM Tris-HCl (pH 8.0), 50 mM NaCl, 7 mM β-mercaptoethanol), 50 nM
oligonucleotide substrate, and varied concentrations of the tested compounds. Purified
TDP1 was added in a final concentration of 1.5 nM.
The TDP1 reaction mixtures were incubated at a constant temperature of 26 ◦C in a
POLARstar OPTIMA fluorimeter (BMG LABTECH, GmbH). Fluorescence intensity was
measured (Ex. 485/Em. 520 nm) every 1 min for 10 min. The efficiency of TDP1 inhibition
was evaluated by comparing the rate of increase in fluorescence of biosensor in the presence
of compound to that of DMSO (1.5%) in control wells. IC50 values were determined using
an 11-point concentration response curve by MARS Data Analysis 2.0 (BMG LABTECH),
and the slope during the linear phase was calculated. The IC50 measurements were carried
out in at least three independent experiments.
2.3.2. TDP1 Activity by gel-Based Assay
Oligonucleotide 5′- FAM-AAC GTC AGG GTC TTC C-tyrosine-3′ was used for the
indication of TDP1 enzyme activity in polyacrylamide gel. The oligonucleotide containing
a natural phosphotyrosine adduct at the 3′-end is a substrate for TDP1 [38]. The reaction
mixture was conducted in the reaction buffer (50 mM Tris-HCl, 50 mM NaCl, 7 mM β-
mercaptoethanol), 50 nM oligonucleotide, 5 nM purified TDP1, or 1 µg of cell extract
in a final volume 20 µL at 37 ◦C for 20 min. The reaction products were separated by
electrophoresis in a 20% denaturing polyacrylamide gel with 7 M urea. A Typhoon FLA
9500 phosphorimager (GE Healthcare, Uppsala, Sweden) was used for gel scanning and
imaging, and the data were analyzed with QuantityOne 4.6.7 software.
2.3.3. TDP1 Knockout HEK293A Clones
TDP1 knockout HEK293A clones were obtained in the same way as the previously
described TDP1 knockout HEK293FT clones [39]. Briefly, two 20-nt protospacer sequences
flanking the first protein coding exon of human TDP1 gene were selected using https:
//www.benchling.com/ (accessed date 1 November 2020). Oligonucleotides were cloned in
plasmid pSpCas9(BB)-2A-GFP (PX458). pSpCas9(BB)-2A-GFP (PX458) was a gift from Feng
Zhang (Addgene plasmid # 48138; http://n2t.net/addgene:48138; RRID: Addgene_48138).
HEK293A cells were transfected with plasmids pX458-TDP1-gRNA1 and pX458-TDP1-
gRNA2 (0.25 µg of each) using Lipofectamine 3000 Reagent (Thermofisher Scientific,
Waltham, MA USA). Growth medium contained DMEM/F12 (Thermofisher Scientific,
Waltham, MA, USA) 1:1, 10% FBS (Thermofisher Scientific, Waltham, MA, USA), 100 U/mL
penicillin–streptomycin (Thermofisher Scientific, Waltham, MA, USA), and 1 × GlutaMAX
(Thermofisher Scientific, Waltham, MA, USA). Forty-eight hours after transfection, the GFP-
positive cell population was enriched by cell sorting using BD FACSAria III Cell Sorter (BD
Biosciences, Franklin Lakes, NJ, USA). Single cell clones grew for two weeks, and genome
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DNA was analyzed on CRISPR/Cas9-mediated deletions in TDP1 gene by PCR ampli-
fication of target region with primers: TDP1-scF 5′-TCAGGAAGGCGATTATGGGAG-3′
and TDP1-scR 5′-TTGATGTGGAGGGCTCCAG-3′. As a result, three HEK293A clones
were found, which contained only alleles with deletions (C6, G6, and F7). PCR products
obtained from genomic DNA of these clones were gel purified and cloned in the pGEM-T
Easy vector (Promega, Madison, WI, USA). Ten independent plasmid clones were isolated
and Sanger sequenced using M13 universal primers.
2.3.4. Cell Culture Cytotoxicity Assay
Cytotoxicity of the compounds was examined against human cell lines HEK293A
(human embryonic kidney)—WT and TDP1-deficient (Tdp1-/-), and HeLa (cervical cancer)
using an EZ4U colorimetric tests (Biomedica, Vienna, Austria) or xCELLigence DP Real-
Time Cell Analyzer (ACEA Biosciences, Santa Clara, CA, USA). Cell lines were obtained
from the Russian Cell Culture Collection (RCCC) Institute of Cytology RAS (St. Peters-
burg, Russia). The cells were grown in DMEM/F12 medium (Thermo Fisher Scientific,
Waltham, MA, USA), with 1× GlutaMAX (Thermo Fisher Scientific, Waltham, MA, USA),
50 IU/mL penicillin, and 50 µg/mL streptomycin (Thermo Fisher Scientific, Waltham, MA,
USA), and in the presence of 10% fetal bovine serum (Biolot, Saint-Petersburg, Russia)
in 5% CO2 atmosphere. Control cells were grown in the presence of 1% DMSO where
indicated. After formation of a 30–50% monolayer, tested compounds were added to the
medium, and the cell culture was monitored for 3 days. The compound concentration that
caused 50% cell growth inhibition (CC50) was determined using OriginPro 8.6.0 software.
The measurements were carried out in three parallel experiments.
2.4. Modelling and Screening
The compounds were docked against the crystal structure of TDP1 (PDB ID: 6W7K,
resolution 1.70 Å) [40], which was obtained from the Protein Data Bank (PDB) [41,42]. The
Scigress version FJ 2.6 program [43] was used to prepare the crystal structure for docking,
i.e., the hydrogen atoms were added and the co-crystallized ligand 4-[(2-phenylimidazo[1,2-
a]pyridin-3-yl)amino]benzene-1,2-dicarboxylic acid (TG7) was removed. The Scigress
software suite was also used to build the inhibitors and the MM2 [44] force field was applied
to identify the global minimum using the CONFLEX method [45], followed by structural
optimization. The docking center for the catalytic pocket was defined as the position of the
nitrogen atom in the amine group of TG7 (x = 10.622, y = −3.446, z = −99.112) with 10 Å
radius. The center for the allosteric site was defined as the oxygen atom in the carboxylic
group pointing into the pocket (x = 18.656, y = −0.525, z = −98.790). Fifty docking runs
were allowed for each ligand with default search efficiency (100%). The basic amino acids
lysine and arginine were defined as protonated. Furthermore, aspartic and glutamic acids
were assumed to be deprotonated. The GoldScore (GS) [46] and ChemScore (CS) [47,48]
ChemPLP (Piecewise Linear Potential) [49] and ASP (Astex Statistical Potential) [50] scoring
functions were implemented to predict the binding modes and relative energies of the
ligands using the GOLD v5.4.1 software suite.
The QikProp 6.2 [51] software package was used to calculate the molecular descriptors
of the molecules. The reliability of QikProp was established for the calculated descrip-
tors [52]. The Known Drug Indexes (KDI) were calculated from the molecular descriptors
as described by Eurtivong and Reynisson [53]. For application in Excel, columns for
each property were created and the following equations were used to derive the KDI
numbers for each descriptor: KDI MW: = EXP(-((MW-371.76)ˆ2)/((2x112.76)ˆ2)), KDI Log
P: = EXP(-((LogP-2.82)ˆ2)/((2x2.21)ˆ2)), KDI HD: = EXP(-((HD-1.88)ˆ2)/((2x1.7)ˆ2)), KDI
HA: = EXP(-((HA-5.72)ˆ2)/((2x2.86)ˆ2)), KDI RB = EXP(-((RB-4.44)ˆ2)/((2x3.55)ˆ2)), and
KDI PSA: = EXP(-((PSA-79.4)ˆ2)/((2x54.16)ˆ2)). These equations could simply be copied
into Excel and the descriptor name (e.g., MW) substituted with the value in the relevant
column. To derive KDI2A, we used the following equation: = (KDI MW + KDI LogP + KDI
Biomolecules 2021, 11, 973 10 of 23
HD + KDI HA + KDI RB + KDI PSA), and for KDI2B: = (KDI MW × KDI LogP × KDI HD
× KDI HA × KDI RB × KDI PSA).
3. Results
3.1. Chemistry
The target UA enamine derivatives 11a–e with terpene substituents were synthesized
by reacting usnic acid and the corresponding terpeneamines 14a–e. The UA derivatives,
with terpene moiety connected to UA via γ-aminobutyric acid (GABA), were synthesized
in two steps. At the first stage, the UA enamine derivative 12 with GABA substituent
was synthesized via reaction of usnic acid with GABA. At the second stage, compound 12
reacted with terpeoles to produce the target UA derivatives 13a–e.
3.1.1. Synthesis of Usnic Acid Enamine Derivatives 11a–e
At first, we synthesized corresponding amines from commercially available monoter-
pene alcohols. A set of monoterpenoid amines of different structural types was synthe-
sized by the Gabriel method [54]. Citronellylamine 14a, geranylamine 14b, nopylamine
14c, myrtenylamine 14d, and perillamine 14e were obtained by bromination of the corre-
sponding alcohols followed by reaction with potassium phthalimide and reduction with
hydrazine to the target amine (Scheme 1). Reaction of (+)-UA 1 with terpenoids 14a–e with
amino group resulted in corresponding conjugates with the enamino structure 11a–e. Thus,
five new compounds, derivatives of UA with mono-, bi-, and acyclic terpene fragments,
were obtained.
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3.1.2. Synthesis of Usnic Acid Enamine De ivatives with an Ether Bon 13a–e
The derivative 12 was synthesized according to a previously developed technique by
reaction of (+)-UA 1 with γ-aminobutyric acid (GABA) (Scheme 2) [34]. GABA was chosen
as an amino acid linker to bind the two pharmacophores on the basis of its availability and
simplification of product characterization as it does not contain chiral centers.
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nopol ere used. Terpene alcohols 15d and 15e ere obtained by reduction of yrtenal
and perillyl aldehyde with sodium borohydride in methanol. Reaction of these alcohols
with 12 led to formation ester derivatives 13a–e with the terpene fragment at the C ring
of UA (Scheme 2). The reaction was carried out in dry methylene at 0 ◦C and in an inert
atmosphere using EDC as a condensing agent and dimethylaminopyridine (DMAP) as
a catalyst.
3.2. Biology
3.2.1. Real-Time Detection of TDP1 Activity
We tested the 10 enamine derivatives of (+)-UA for their TDP1 inhibitory properties
by deriving their IC50 values (the inhibitor concentration required to suppress the activity
of enzyme by 50%) using a real-time fluorescent test according to the method we devel-
oped [36]. Enamine derivatives in which the terpene fragment is connected to the (+)-UA
scaffold via a linker with an ester bond (compounds 13a–e) did not show pronounced TDP1
inhibition (IC50 ≥ 10 µM, Table 5). At the sa e time, terpene–UA conjugates obtained by
direct condensation of UA with primary terpenoid amines (compounds 11a–d) showed
inhibitory activity at submicromolar concentrati ns. IC50 values for the most effective
i i it rs (11a, 11b, 11c, 11d) varied in a narrow ra ge of .23–0.40 µM. Thus, the inhibitory
activity only slightly depends on the st uctu e of the terpene part, excluding 11e with
monocyclic para-menthan fragment.
Thus, compounds containing a acyclic (11a, 11b) or bicyclic (11c, 11d) terpene fragment
proved to be potent inhibitors of TDP1, and they were selected for cytotoxicity studies.
3.2.2. Cell Culture Cytotoxicity Assay
Th intrinsic cytotoxicity of the four lead compounds (11a–d) was examined using a
colorimetric test (Figure 6). The derivatives exhibited low cytotoxicity (CC50 ≥ 60 µM) for
both HeLa and HEK293A cells, and the dose response graphs are shown in Figure 6 and
Figure S1.
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Table 5. The influence of UA derivatives 11a–e and 13a–e on TDP1 activity.
Terpene Fragment
Structure
Code IC50, µM Code IC50, µM
11a–e 13a–e
11a 0.40 ± 0.09 13a >10
11b 0.32 ± 0.13 13b >10
11c 0.32 ± 0.10 13c >10
11d 0.23 ± 0.10 13d >10
11e >10 13e >10
Figure 6. The TDP1 inhibitors’ intrinsic cytotoxicity on HeLa (a) and HEK293A (b) cells—dose-dependent action.
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As can be seen in Figure 6, both 11b and 11d were more cytotoxic than 11a and 11c;
the former completely suppressed cell growth at 100 µM. 11a and 11c, with acyclic terpene
fragment, are effective TDP1 inhibitors and non-cytotoxic for HeLa and HEK293A cells.
Low intrinsic cytotoxicity of TDP1 inhibitors is desired for their use as sensitizers with,
e.g., Tpc.
3.2.3. Potentiation with Topotecan
In our previous work [39], the cytotoxic effect of Tpc and the TDP1 inhibitors, monoter-
pene 3-carene derivatives, was established; both were measured separately and jointly
using a panel of HEK293FT TDP1 knockout isogenic clones. It was shown that HEK293FT
TDP1-/- cells were more sensitive to Tpc compared to WT (wild-type) cells. The data on
HEK293FT mutants were of low reproducibility due to the weak cell adherence; it was
therefore decided to change the cell line to HEK293A. In this work, we created a new panel
of TDP1-/- HEK293A cells using the CRISPR/Cas9 and polymerase chain reaction (PCR)
screening of cell clones (Figure S21). Three clones contained deletions in the first protein
coding exon of TDP1 gene: clone C6 ∆196bp/∆197, clone G6 ∆197bp/∆197bp, and clone
F7 ∆198bp/∆196bp (Figures S21 and S22A). The clones C6, G6, and F7 were screened by
a biochemical assay for 3′-phosphotyrosyl cleavage to identify TDP1 activity in the cell
extract (Figure S22B). No cleavage activity was detected in the clones’ C6, G6, and F7 cell
extracts in contrast to control WT and purified TDP1. We treated TDP1-proficient (WT) and
TDP1-deficient (TDP1-/-) cells with increasing concentrations of Tpc. The results for the
three clones are presented in Figure 7. The same effect was seen as for the HEK293FT cell
line [39], and TDP1-/- cells of the HEK293A cell line were more sensitive to Tpc compared
to WT (Figure 7).
Figure 7. Topotecan (Tpc) cytotoxicity in HEK293A WT and TDP1 -/- knockout cell lines C6, G6 and
F7—dose-dependent action of Tpc by colorimetric test.
TDP1 can work against the action of Tpc, cleaving the TOP1–DNA stalled complex.
Next, we checked the cytotoxic effect of the combination of Tpc and 11a–d as compared to
Tpc in the HeLa cancer cells and non-cancerous HEK293A WT and TDP1-/- cells.
Surprisingly, when we added combination of Tpc and the inhibitors (11a and 11c) to
the HEK293A cells, a stimulation of cell growth was observed as compared to Tpc for both
WT (Figure 8) and Tdp1-/- cells (Figure S23). There was no difference between WT and the
mutant cells.
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Figure 8. Topotecan (Tpc) cytotoxicity on HEK293A WT cells—dose-dependent action of Tpc in combination with 11a (a) or
11c (b).
This stimulation was also confirmed for HEK293A WT cells using the xCELLigence
DP Real-Time Cell Analyzer impedance-based assay (Figure 9). As seen previously, 11c
was non-toxic and 11a was modestly toxic for HEK293A cells (Figure 9A, dark green and
violet). The stimulation effect depends on the concentration of compounds 11a and 11c
(Figure 9B,C). Thus, both 11a and 11c stimulated cell growth of non-cancerous HEK293A
cells when dosed with Tpc.
Figure 9. Compounds 11a and 11c stimulated cell growth of HEK293A WT cells with Tpc, as compared to Tpc, using the
impedance-based real-time assay. (A). Cell growth of HEK293A cells in the control wells without compounds added (black),
with 50 nM Tpc (red), 40 µM 11a (dark green), or 40 µ M 11c (violet). (B,C) Cell growth of HEK293A cells with 50 nM Tpc
only (red) and in combination with 5 µM (green), 10 µM (dark blue), 20 µM (pink), or 40 µM (blue) 11a (B) or 11c (C).
In cancer HeLa cells, all four TDP1 inhibitors showed promising synergy in conjunc-
tion with Tpc (Figure 10). The combination index (CI) values were determined for different
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concentrations of Tpc and the enamines 11a–d at 2 and 5 µM. They were predominantly
in the range 0.5–0.8, indicating a synergistic effect between Tpc and the UA derivatives.
The CI values were calculated with the CompuSyn version 1.0 software. The CI plot at
different fraction-affected (Fa) was determined for Tpc (0.3, 0.5, 1, 2, and 4 µM) and the
Tdp1 inhibitors (2 and 5 µM). The CI values for most of the combinations corresponded to
a synergistic effect (CI < 1, see Figure S24 in the Supplementary Materials).
Figure 10. Dose-dependent action of the Tpc with 11a, 11b, 11c, and 11d (5 µM) on HeLa cells’ viability.
Both 11a and 11c showed synergistic effect with Tpc reducing viability in the HeLa
cell line, but stimulated cell growth of non-cancerous HEK293A cells.
3.3. Modelling and Screening
The 10 UA enamine derivatives were docked into the binding site of the TDP1 structure
(PDB ID: 6W7K, resolution 1.70 Å) [40]. The co-crystalized ligand (TG7) was removed and
re-docked into the binding site to test the robustness of the scoring functions GoldScore
(GS) [46] and ChemScore (CS) [47,48] ChemPLP (Piecewise Linear Potential) [49] and ASP
(Astex Statistical Potential) [50] in the GOLD (v2020.2.0) docking algorithm (the validation
of the quality of the docking algorithm is given in Table S1).
It has been suggested, on the basis of molecular dynamics simulations, that the
UA enamines occupy an allosteric site next to the catalytic pocket, thus reducing TDP1
activity [15]. This pocket is made up of the Tyr204, Cys205, Asp230, Lys231, Leu255,
Ala258, Phe259, and Thr261 amino acid residues, which can form hydrophobic contacts
and hydrogen bonding interactions with small molecular ligands. The ligands were docked
to this site, and in most cases, the GOLD algorithm directed the ligands into the catalytic
pocket, predicting the same, or similar, conformations as seen previously. Simulating DNA
occupancy of the catalytic pocket by leaving the co-crystallized inhibitor in it directed the
docking to the allosteric site. The scores generated were realistic (see Table S2); correlations
with the measured IC50 values were seen, but the slope of the fitted line was positive, i.e.,
the higher the scores, the poorer the inhibition. Moreover, the averages of the inactive
ligands (>10 µM) were higher than for those with good activity.
It can therefore be concluded that both scenarios were possible, and that potentially
both took place in the assay and biological systems. This question can be answered
with X-ray crystallography. The predicted binding of 11d is given in Figure 11 for both
binding sites.
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Figure 11. The docked poses of 11d in both potential binding sites of TDP1 as predicted by the ASP scoring function.
(A) The allosteric site is to the left-hand side, and the ligand’s predicted conformation is shown in stick format. The catalytic
pocket is to the right-hand side, and the ligand is depicted as balls and sticks, reaching into the allosteric pocket with its
aliphatic bicyclic ring (see circled area). The co-crystalized ligand is shown (green lines) buried in the catalytic pocket.
The protein surface is rendered; blue depicts regions with a partial positive charge on the surface, red depicts regions with
a partial negative charge, and gray shows neutral areas. (B) Allosteric site: The predicted configuration is shown in the
stick format as well as Tyr204, Cys205, and Asp230, which formed hydrogen bonds (green lines) to the ligand. Adjacent
amino acid residues buttressing the ligand are shown in the line format (Lys231, Ala234, Phe259, Gly260, Thr261); the
hydrogen atoms are not shown for clarity. (C) Catalytic pocket: The predicted configuration depicted as balls and sticks
with hydrogen bonding amino acid residues Thr261 and His493. The adjacent amino acids are Tyr204, Gly229, Asp230,
Lys231, Phe259, Gly260, Ser399, Ser400, Pro461, and Asn516.
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As can be seen in Figure 11A, the 6,6-dimethylnopin-2-ene ring occupied both binding
sites, i.e., the UA scaffold was predicted to be buried in the catalytic pocket whereas the
aliphatic ring stretched into the allosteric site. In both scenarios, plausible binding was
observed, with hydrogen bonding anchoring the ligand in place as well as scaffolding of
lipophilic amino acid residues buttressing the bound ligand. The predicted conformation
in the allosteric site was more exposed to the aqueous phase as compared to the binding in
the catalytic pocket.
When the predicted conformations were analyzed, then the derivatives with long
aliphatic chains (13a–e) did not fit into the binding domain; the aliphatic chain was too
long to allow for the binding of the UA scaffold into the catalytic pocket and for the
aliphatic rings, or saturated chains, to fit in the allosteric binding pocket, as shown in
Figure 11A, C for 11d. The rest of the ligands (11a, 11b, and 11c) had relatively short
chains and predominantly were predicted, by the scoring functions used, to adopt the
same conformation as 11d in the catalytic pocket. Interestingly, compound 11e did not
have inhibitory activity (IC50 > 10 µM), even though it is a close analogue of 11d; when the
binding of 11e was analyzed, only CS predicted a clear bind mode with the UA moiety in
the catalytic pocket and the aliphatic ring in the allosteric binding site. Ample hydrogen
bonding was predicted for the UA to various amino acid residues in the catalytic pocket, but
no hydrogen bonding was seen in the allosteric site. This means that the monocyclic ring
did not fit well into the allosteric site and did not facilitate hydrogen bonding anchoring it
in place, in comparison with 11d that formed a hydrogen bond with Thr261 in the allosteric
site. From these observations, a plausible binding mode is presented in Figure 11A, C for
the catalytic pocket, which agrees with the structure–activity relationship.
3.4. Chemical Space
The calculated molecular descriptors MW (molecular weight), log P (water-octanol
partition coefficient), HD (hydrogen bond donors), HA (hydrogen bond acceptors), PSA
(polar surface area), and RB (rotatable bonds)) are given in Table S3. The values of the
molecular descriptors lay within drug-like chemical space and Known Drug Space (KDS),
except for HD, which was in lead-like space. HA and RB were in drug-like chemical space,
whereas the rest of the descriptors straddled drug-like space and KDS (for the definition
of lead-like, drug-like, and KDSregions, see [55] and Table S4). Interestingly, when the
descriptor values were correlated with their IC50 counterparts, albeit only four, very good
correlation was seen for RB (R2—0.799); Log P (R2—0.849); and, to a lesser extent, PSA
(R2—0.332). When one outlier (11c) was removed from MW, then an almost perfect cor-
relation of R2—0.999 was derived (see Figures S25–S28 in the Supplementary Materials).
In all four cases, smaller descriptor values led to improved inhibition. In addition, when
the averages were calculated for the active and inactive (IC50 >10 µM) derivatives, consid-
erably smaller values were seen for all the molecular descriptors used, except HD for the
active derivatives (see Table S2). This led to the conclusion that smaller compounds are
favorable for the UA enamines. Correlations between the molecular descriptors and their
corresponding binding efficacies to TDP1 have been previously reported for deoxycholic
acid derivatives, MW of R2—0.452 and of 0.316 for RB, [56] as well as for sultone-fused
berberine derivatives for MW (R2—0.735) and log P (R2—0.613) [57].
The Known Drug Indexes (KDIs) for the ligands were calculated to gauge the balance
of the molecular descriptors (MW, log P, HD, HA, PSA, and RB). This method is based
on the analysis of drugs in clinical use, i.e., the statistical distribution of each descriptor
is fitted to a Gaussian function and normalized to 1, resulting in a weighted index. Both
the summation of the indexes (KDI2a) and multiplication (KDI2b) methods were used [53],
as shown for KDI2a in Equation (1) and for KDI2b in Equation (2); the numerical results are
given in Table S3 in the Supplementary Materials section.
KDI2a = IMW + Ilog P + IHD+ IHA + IRB + IPSA 2) (1)
KDI2b = IMW × Ilog P × IHD× IHA × IRB × IPSA 3) (2)
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The KDI2a values for the ligands ranged from 3.43 to 5.27, with a theoretical maximum of
6 and the average of 4.08 (±1.27) for known drugs. The KDI2b range was from 0.01 to 0.46, with
a theoretical maximum of 1 and with a KDS average of 0.18 (±0.20). When the KDI values of
the active ligands were plotted against their IC50s, excellent correlations were seen with KDI2A
(R2—0.859) and KDI2B (R2—0.861, see Figures S29 and S30); furthermore, the averages for the
active ligands were considerably higher than for the inactive (IC50 > 10 µM) derivatives.
In conclusion, activity for the enamine ligands was improved with smaller descriptor
values, which fit the modelling observation that only relatively short aliphatic chains
are tolerated.
4. Discussion
The search for inhibitors of the DNA repair system is a promising area of modern
pharmacology that could increase the effectiveness of cancer therapy, especially to drug-
resistant tumors. An interesting target for cancer treatment is TDP1, which plays a key
role in the removal of DNA damage produced by TOP1 inhibition by clinically important
anticancer drugs (irinotecan, Tpc) as well as removal of DNA damage caused by other
anticancer drugs.
A literature review of known TDP1 inhibitors showed that the most effective pharma-
cophoric fragments are of natural products, i.e., a class of phenols (UA [12–15,24,25]) and
terpenes (monoterpenoids [28–30,58–60]).
As mentioned in the introduction, the addition of a terpene substituent in the TDP1
inhibitor framework leads to a decrease in both effective inhibitory concentration and,
in particular, general cytotoxicity. For example, arylidenefuranone compounds inhibit
the growth of HEK293 cells in the concentration range of 4.6 to 20 µM [13], while some
terpene-furanone derivatives were found to be toxic to these cells from 9 µM [31]. Enamine
UA derivatives are generally less cytotoxic than hydrazinothiazole derivatives, e.g., 4
inhibited the growth of MCF-7 cells by half at 1.7 µM [12], and its enamine analog, with a
para-bromophenyl substituent, at 40 µM [15].
In this study, we synthesized a series of new UA enamino derivatives with terpene
fragments, hoping to obtain more effective and less toxic sensitizers to be used with Tpc.
The derivatives varied both in the structure of the terpene fragment (linear, monocyclic,
bicyclic) and in the linker length. Moreover, these compounds were easier to synthesize in
comparison with known UA-based TDP1 inhibitors. Four compounds (11a–d) exhibited
IC50 values in the range of 0.23–0.40 µM (Table 1), which was approximately the same
as the values for enamines with aryl substituents (0.16–2 µM) [15]. Their analogs with
longer substituents 13a–d did not affect the enzyme activity at concentrations of up to
10 µM. Surprisingly, compound 11e did not inhibit the enzyme, although its substituent
did not differ in size from 11ds substituent, the most effective inhibitor of the entire set.
According to molecular modelling, compound 11e did not form a single hydrogen bond in
the allosteric center, in contrast to 11d, explaining the difference in efficacy.
It was shown by molecular modelling that the UA enamines can occupy both the
catalytic and allosteric sites. The effective TDP1 inhibitors 11a–d have short aliphatic
chains and were predicted to adopt a conformation occupying both the catalytic pocket
and the allosteric site. The derivatives with long aliphatic chains, with no TDP1 activity
at micromolar concentrations (13a–e), did not fit into both binding domains (Figure 11, C
for 11d). Furthermore, there was a clear correlation of activity of the enamine ligands and
smaller descriptor values. This explains why only relatively short aliphatic chains were
tolerated. Earlier, we also reported the binding of UA enamines in the allosteric center near
the catalytic center, on the basis of molecular dynamics simulations [15].
The intrinsic cytotoxicity of the UA-derived TDP1 inhibitors were checked in two
human cell lines, HeLa and HEK293A. The compounds demonstrated low cytotoxicity
with CC50 values > 60 µM for both cell lines. Low, or insignificant, cytotoxicity of new
potential substances for drug combination therapy is important to avoid side effects.
By increasing the sensitivity to conventional cytotoxic therapy using a non-toxic agent, it is
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possible to reduce the toxic load on the patients, making the regime more tolerable. This is
very important because many cancer patients are elderly, often with underlying medical
conditions, who cannot tolerate an aggressive treatment. We selected two candidates (11a
and 11c) for the studies on cell cultures in combination with Tpc on the basis of their TDP1
efficacy and low cytotoxicity. We observed synergistic effect with Tpc for 11a and 11c—both
compounds enhanced Tpc cytotoxicity on cancerous HeLa cell line. We obtained three
TDP1 knockout clones of the HEK293A cell line to confirm that the cellular target of the
compounds was TDP1, as previously performed for TDP1 -/- mutants of the HEK293FT
line [39]. To our surprise, sensitization was not seen with Tpc in either WT HEK293A cells
or TDP1 -/- cells. Adding both Tpc and TDP1 inhibitor (11a or 11c) to HEK293A cells led
to the stimulation of growth as compared to only Tpc.
5. Conclusions
Cancers are one of the most frequent causes of death in the world. There are several
problems arising in the course of chemotherapeutic treatment of oncological diseases,
namely, low efficiency of chemotherapy, the resistance of malignant tumors to drugs, many
side effects, and a strong toxic load on the body. The cytotoxic effect of chemotherapy
is caused by the ability to create DNA damage in cancer cells, and DNA repair is a key
mechanism of resistance. The design of new compounds that inhibit DNA repair enzymes
is a promising strategy for potentiating the cytotoxicity of DNA damaging agents that are
clinically used as therapeutic agents. The enzymes involved in DNA repair, for example,
TDP1, are interesting therapeutic targets.
In this work, we chose two compounds (11a and 11c) as favorable candidates for anti-
cancer therapy in combination with Tpc. They were selected out of 10 newly synthesized
UA enamino derivatives with terpene fragments on the basis of their TDP1 inhibitory
properties and low intrinsic cytotoxicity on HeLa and HEK293A cells. Both compounds
enhanced Tpc cytotoxicity on cancerous HeLa cell line but reduced it on non-cancerous
HEK293A cells. This “protective” effect from Tpc on non-cancerous cells could be a posi-
tive advantage but needs further investigation as well as a search of other cellular protein
targets for these UA derivatives.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/biom11070973/s1, Figures S1–S19: NMR 13C spectra of compounds. Figure S20: TDP1
inhibitors’ intrinsic cytotoxicity on HEK293A WT and TDP1 -/- cells (C6, G6, F7), and dose-dependent
action of the derivatives 11a, 11b, 11c, and 11d. Figure S21: Verification of CRISPR/Cas9-mediated
deletions in the TDP1 gene by genome DNA sequencing. Alignment of plasmid clones sequenograms
(C6, G6, F7) with the wild-type sequence of the TDP1 gene revealed the presence of deletions that
shift the reading frame and potentially disrupt the synthesis of the corresponding protein. Figure S22:
Analysis of the HEK293 TDP1 -/- clones. (A) PCR analysis for the presence of CRISPR/Cas9-mediated
deletions in TDP1 gene. PCR analysis showed homozygous deletions in the first protein coding
exon (third exon in mRNA, NM_001008744.2) of the TDP1 gene in clones C6, G6, and F7 (lanes
3–5). (B) Identification of TDP1 3′-phosphotyrosyl cleavage activity in the HEK293 cell extracts:
HEK293FT WT (lane 3); HEK293A WT (lane 4); and clone C6, G6, and F7 cells (lanes 5–7). There was
no established cleavage activity in the clone C6, G6, and F7 cell extracts, in contrast to control WT cell
extracts and purified TDP1. Figure S23: Topotecan cytotoxicity on HEK293A TDP1 -/- (clones C6, G6,
and F7) cells, and dose-dependent action of topotecan in combination with 11a or 11c compounds by
colorimetric test. Figure S24: Topotecan cytotoxicity on HeLa cells, and dose-dependent action of
topotecan in combination with 11a (left) or 11c (right) compounds by colorimetric test and CompuSyn
version 1.0 software. Table S1: The binding affinities as predicted by the scoring functions used to
the catalytic binding site. Table S2: The binding affinities as predicted by the scoring functions used
to the allosteric binding site. Table S3: The molecular descriptors and their corresponding Known
Drug Indexes 2a and 2b (KDI2a/2b). The R2 numbers derived do not contain the IC50 > 10 µM values.
Table S4: Definition of lead-like, drug-like, and Known Drug Space (KDS) in terms of molecular
descriptors. The values given are the maxima for each descriptor for the volumes of chemical space
used. Figure S25: The correlation of the IC50 values of the active ligands with RB. Figure S26: The
correlation of the IC50 values of the active ligands with MW. 11c was an outlier and was not included
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in the R2. Figure S27: The correlation of the IC50 values of the active ligands with Log P. Figure S28:
The correlation of the IC50 values of the active ligands with PSA. Figure S28: The correlation of the
IC50 values of the active ligands with KDI2A. Figure S30: The correlation of the IC50 values of the
active ligands with KDI2B.
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